ROCO
1784
Market cap156mUSD
Feb 24, Last price
104.50TWD
1D
3.98%
1Q
8.29%
Jan 2017
244.88%
IPO
72.30%
Name
Bionet Corp
Chart & Performance
P/E
58.62
P/S
4.02
EPS
1.78
Div Yield, %
1.36%
Shrs. gr., 5y
—
Rev. gr., 5y
4.50%
Revenues
1.22b
+8.40%
Net income
84m
+6.76%
CFO
176m
+15.28%
Dividend
Oct 03, 20251.41629 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products. In addition, the company offers Exosome, a novel cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||